MSLN and neoplasm: These findings could be explained by a threshold effect whereby 89Zr-amatuximab is mostly bound to shed MSLN in blood at the lower dose (10 μg) and sequestered into the reticular endothelial system of liver and spleen, thereby lowering both blood retention and tumor uptake.